EA201001224A1 - Химические соединения, композиции и способы их использования - Google Patents

Химические соединения, композиции и способы их использования

Info

Publication number
EA201001224A1
EA201001224A1 EA201001224A EA201001224A EA201001224A1 EA 201001224 A1 EA201001224 A1 EA 201001224A1 EA 201001224 A EA201001224 A EA 201001224A EA 201001224 A EA201001224 A EA 201001224A EA 201001224 A1 EA201001224 A1 EA 201001224A1
Authority
EA
Eurasian Patent Office
Prior art keywords
skeletal
methods
chemical compounds
muscle
compositions
Prior art date
Application number
EA201001224A
Other languages
English (en)
Inventor
Зхе Янг
Скотт Коллайби
Алекс Муци
Джианчао Ванг
Джефф Гардина
Льюк В. Ашкрафт
Брайан Стольц
Густав Берджинс
Брэдли П. Морган
Original Assignee
Цитокинетикс, Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цитокинетикс, Инкорпорейтед filed Critical Цитокинетикс, Инкорпорейтед
Publication of EA201001224A1 publication Critical patent/EA201001224A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Представлены некоторые химические соединения и способы использования для модуляции скелетного миозина, скелетного актина, скелетного тропомиозина, скелетного тропонина С, скелетного тропонина I, скелетного тропонина Т и скелетной мышцы, включая их фрагменты и изоформы, а также скелетный саркомер, и способы использования при лечении нейромышечных нарушений, состояний с атрофией мышц, хромоты, дряхлости, метаболического синдрома, мышечной атрофии, связанной с неиспользованием, и мышечной усталости, и других показаний.
EA201001224A 2008-02-04 2009-02-02 Химические соединения, композиции и способы их использования EA201001224A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2606708P 2008-02-04 2008-02-04
PCT/US2009/000686 WO2009099594A1 (en) 2008-02-04 2009-02-02 Certain chemical entities, compositions and methods

Publications (1)

Publication Number Publication Date
EA201001224A1 true EA201001224A1 (ru) 2011-08-30

Family

ID=40952391

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001224A EA201001224A1 (ru) 2008-02-04 2009-02-02 Химические соединения, композиции и способы их использования

Country Status (18)

Country Link
US (2) US7989469B2 (ru)
EP (1) EP2244711A4 (ru)
JP (1) JP2011510985A (ru)
KR (1) KR20100119773A (ru)
CN (1) CN101983061A (ru)
AR (1) AR072242A1 (ru)
AU (1) AU2009210787A1 (ru)
BR (1) BRPI0907502A2 (ru)
CA (1) CA2713864A1 (ru)
CL (1) CL2009000246A1 (ru)
CO (1) CO6290673A2 (ru)
EA (1) EA201001224A1 (ru)
EC (2) ECSP10010430A (ru)
IL (1) IL207367A0 (ru)
MX (1) MX2010008518A (ru)
TW (1) TW200946524A (ru)
WO (1) WO2009099594A1 (ru)
ZA (1) ZA201005780B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
ES2547687T3 (es) 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
IN2014DN00200A (ru) 2011-07-13 2015-06-05 Cytokinetics Inc
KR102163931B1 (ko) * 2012-04-11 2020-10-12 싸이토키네틱스, 인코포레이티드 골격근 피로에 대한 저항을 개선
SI3137622T1 (sl) 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
TWI794369B (zh) * 2017-12-14 2023-03-01 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
WO2020240586A1 (en) * 2019-05-28 2020-12-03 Mankind Pharma Ltd. Novel compounds for inhibition of janus kinase 1
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
WO2005002520A2 (en) 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
ES2558517T3 (es) 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
ES2381215T3 (es) 2006-10-19 2012-05-24 Signal Pharmaceuticals Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
EP2139478A4 (en) * 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Ｍｌｋ阻害剤および使用方法

Also Published As

Publication number Publication date
CA2713864A1 (en) 2009-08-13
ECSP10010432A (es) 2011-01-31
WO2009099594A1 (en) 2009-08-13
CN101983061A (zh) 2011-03-02
CO6290673A2 (es) 2011-06-20
US20090253737A1 (en) 2009-10-08
US20110312975A1 (en) 2011-12-22
CL2009000246A1 (es) 2009-06-26
EP2244711A1 (en) 2010-11-03
MX2010008518A (es) 2010-11-10
BRPI0907502A2 (pt) 2019-01-15
ZA201005780B (en) 2011-04-28
ECSP10010430A (es) 2011-02-28
IL207367A0 (en) 2010-12-30
TW200946524A (en) 2009-11-16
EP2244711A4 (en) 2011-08-24
US7989469B2 (en) 2011-08-02
AU2009210787A1 (en) 2009-08-13
JP2011510985A (ja) 2011-04-07
AR072242A1 (es) 2010-08-18
KR20100119773A (ko) 2010-11-10

Similar Documents

Publication Publication Date Title
EA201001224A1 (ru) Химические соединения, композиции и способы их использования
WO2008016648A3 (en) Certain chemical entities, compositions and methods
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
EA200970729A1 (ru) Варианты, происходящие из actriib, и их применение
ME00380B (me) Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
BR122020000059B8 (pt) composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
UY33280A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
EA200701439A1 (ru) Pyy-агонисты и их применение
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
HN2012002664A (es) Compuestos, composiciones de tioacetato y metodos de uso
ECSP077180A (es) Compuestos, composiciones y métodos
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201070423A1 (ru) Диарильные соединения оксадиазолов
EA201491666A1 (ru) Способы повышения устойчивости скелетных мышц к утомлению
EA201000550A1 (ru) Производные тиазола
EA202091803A1 (ru) Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
EA201201623A1 (ru) Лечение диабета 2 типа
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου